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Abstract 
Membranous nephropathy is a cause of the nephrotic syndrome in adults; it can be a primary 
or secondary process. Secondary causes include solid organ and lymphoid malignancies. Pros-
tate cancer has been reported as the second most common causative malignancy. Remission 
of membranous nephropathy following treatment of metastatic prostate cancer is well estab-
lished. In this case, we describe a patient with localised prostate cancer who developed severe 
nephrotic syndrome (urine protein creatinine ratio 1,616 mg/mmol and serum albumin 17 g/L) 
secondary to membranous nephropathy. The prostate cancer was deemed of low risk and so 
was being managed with active surveillance rather than medical treatment. Given the severity 
of the nephrotic syndrome a trial of androgen deprivation therapy with bicalutamide was 
agreed between the nephrology and urology teams. Full remission of the nephrotic syndrome 
was observed within 6 months of commencement of treatment (normalisation of serum albu-
min, non-nephrotic range urine protein creatinine ratio and resolution of oedema). The bicalu-
tamide has been continued indefinitely. © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Membranous nephropathy is a pathological disease characterised by fine, granular, im-
mune deposits of IgG and complement components in the subepithelial space with thickening 
of the glomerular basement membrane. Glomerular basement membrane extending round 
subepithelial deposits may be seen as “spikes” on silver stains under light microscopy; subep-
ithelial electron-dense deposits are seen on electron microscopy. Membranous nephropathy 
is the most common cause of nephrotic syndrome in adults accounting for around 20% of 
cases [1]. The disease can occur as a primary or secondary process, with secondary causes 
including malignancies, infections, autoimmune disease and drug toxicities [2]. We report the 
first case of remission of membranous nephropathy in a patient with localised prostate cancer 
who would not otherwise have received medical treatment.  
Case Report 
A 75-year-old man was referred to the nephrology clinic with a 3-month history of pro-
gressive oedema involving his legs, abdomen and scrotum associated with orthopnoea and 
fatigue. He had mild, long-standing, lower urinary tract symptoms relating to known prostatic 
enlargement. He had been commenced on oral frusemide which had stabilised his fluid  
retention. 
His past medical history included localised adenocarcinoma of the prostate, <5% Gleason 
3 + 4 disease on the right side of the gland and 1% Gleason 3 + 3 disease on the left diagnosed 
on prostate biopsy 1 year previously. This followed surveillance for a raised prostate-specific 
antigen (PSA) and identification of two suspicious lesions on MRI scan (PI-RADS 4/5) on the 
left side of the gland. He also had a history of ischaemic heart disease, coeliac disease (diag-
nosed 6 years prior and now stable and asymptomatic on a gluten-free diet), diverticulosis, 
colonic polyps with low-grade dysplasia and skin lesions in the form of two previous basal cell 
carcinomas and melanoma in situ which had all been fully excised. He was not taking any ne-
phrotoxic medications. There was no family history of renal disease. He had never smoked. 
On examination, he was normotensive (blood pressure 142/82) with an elevated jugular 
venous pressure and a clear chest to auscultation. He had peripheral oedema to mid abdomen 
and his weight, at 105 kg, was estimated to be 20 kg above his normal body weight.  
Initial investigations showed a urine dipstick positive for protein 3+ and blood 3+. He had 
nephrotic range proteinuria with a urine protein creatinine ratio (uPCR) elevated at 722.5 
mg/mmol. His serum albumin was low at 21 g/L with renal function within the normal range, 
creatinine 62 µmol/L, urea 5.9 mmol/L, eGFR >90 mL/min; his cholesterol was 6.9 mmol/L. 
His current PSA was 6.13 µg/L (reference range 0–5), which had remained stable over the 
past 2 years. A renal immunological screen including anti-nuclear antibody, anti-neutrophil 
cytoplasmic antibody titre and anti-glomerular basement membrane was negative. His com-
plement levels were normal. An ultrasound scan of the renal tract revealed normal renal size 
and morphology and no other abnormalities. His chest X-ray showed small bilateral pleural 
effusions, the lungs were otherwise clear, his heart size and mediastinal contour were normal. 
A clinical diagnosis of nephrotic syndrome was made, and he underwent a renal biopsy 
to obtain a histological diagnosis. Membranous nephropathy was confirmed on biopsy. Light 
microscopy showed 13 glomeruli, none of which were globally sclerosed. The glomeruli were 
normocellular with patent capillary loops. There was subtle capillary wall thickening, but no 
spikes or double contouring were seen on silver stain. There was no interstitial inflammation, 
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oedema or scarring. Immunofluorescence was strongly positive for immunoglobulin G depos-
ited in a granular pattern. On electron microscopy, there were abundant subepithelial immune 
deposits with basement membrane spike formation and extensive epithelial foot process ef-
facement. 
He was negative for serum anti-phospholipase A2 antibody (anti-PLA2R), which raised 
the possibility of a secondary membranous nephropathy. Testing for anti-thrombospondin 
type 1 (anti-THSD7A) was also negative. Viral serology for hepatitis B, C and HIV were all neg-
ative. Given his history of skin cancers he had a skin examination by a dermatologist that did 
not reveal any suspicious lesions. Initial treatment was a watch-and-wait approach with diu-
retics, angiotensin-converting enzyme inhibition and a statin. 
Despite this, his uPCR continued to rise to 1,325 mg/mmol in combination with a fall in 
his albumin to 17 g/L. Given his falling albumin, he was commenced on warfarin anti-coagu-
lation. His underlying low-grade prostate malignancy seemed a possible cause for his severe 
membranous nephropathy and so a further opinion was sought from the urologists. 
His prostate cancer was thought to be of low to intermediate risk and he was being man-
aged with active surveillance through serial PSA readings, which were remaining stable at 
6.13 µg/L when he was diagnosed with nephrotic syndrome. There was no pelvic lymphade-
nopathy on the MRI scan of his prostate at the time of his prostate biopsy. An up-to-date CT 
scan of his abdomen and pelvis showed pleural fluid, ascites and oedema in keeping with ne-
phrotic syndrome but no obvious primary tumour or metastases. There were bilateral pelvic 
lymph nodes measuring up to 13 mm in diameter. Given his very stable and indolent disease, 
the urologists were initially unconvinced that the prostate cancer could be associated with the 
membranous nephropathy. However, after further discussion in a urology cancer multi-disci-
plinary team meeting with attendance and discussion by the nephrologists, it was agreed that 
a trial of androgen deprivation therapy with bicalutamide would be carried out. 
One month after the commencement of treatment with bicalutamide, there was an im-
provement in his peripheral oedema in combination with a rise in serum albumin (23 g/L) 
and fall in uPCR (830 mg/mmol from a peak of 1,616 mg/mmol). Warfarin was stopped at this 
point. The trend continued over the following months and 6 months following treatment he 
was deemed in full remission with complete resolution of oedema, and normalisation of se-
rum albumin to 35 g/L and uPCR now non-nephrotic range at 337 mg/mmol (Fig. 1). As a 
result, in view of his rapid response, a decision to continue the bicalutamide indefinitely, so 
long as it was well tolerated, was agreed at the subsequent multi-disciplinary team meeting. 
Proteinuria continued to normalise and most recently, at 12 months, uPCR was 66 mg/mmol. 
A repeat MRI scan of the pelvis showed no lymphadenopathy. 
Discussion/Conclusion 
Membranous nephropathy can be a primary or secondary process with secondary mem-
branous nephropathy accounting for 20% cases. The IgG4 autoantibody to the podocyte mem-
brane antigen PLA2R has been strongly associated with primary membranous disease [3]. A 
second IgG4 antibody specific for THSD7A, another podocyte membrane antigen, has been 
identified in 2–5% patients. There is a higher frequency of associated malignancies and a fe-
male predominance with anti-THSD7A [4]. Our patient was negative for both anti-PLA2R and 
anti-THSD7A antibodies. 
The first report of an association between prostatic malignancy and development of 
membranous nephropathy was in 1986 [5]. Further literature since then has supported the 
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link between prostatic malignancy and membranous disease [6]. These reports have, how-
ever, largely described this association in the context of metastatic prostatic disease rather 
than the localised cancer described in our case. A recent systematic review and meta-analysis 
of observational studies investigating the link between malignancy and membranous disease 
identified prostate malignancy as being the second most common cancer to be associated with 
membranous disease [2]. This frequency is much higher than previously reported and the au-
thors attribute this to recent studies which reflect increased screening practices for prostate 
cancer, and therefore a higher diagnosis rate. The paper does not, however, describe how the 
cases were treated or the long-term outcomes of these patients. 
Current NICE guidelines for the management of prostate cancer are based on the per-
ceived risk as defined by a combination of PSA, Gleason score and clinical stage [7]. Patients 
with a low risk, as in our case, should be offered an active surveillance approach with consid-
eration of radical prostatectomy at a later stage if there is localised disease progression. Cur-
rent guidelines do not advise on the management of para-neoplastic associations and impact 
on treatment. 
The management of a membranous nephropathy occurring in the context of a dissemi-
nated prostate cancer involves treating the underlying malignancy and assessing response. 
There is, however, limited evidence to support the best treatment methods when membra-
nous nephropathy is associated with low-grade or indolent malignancies. We think that this 
case is interesting because it describes, for the first time, the complete remission of nephrotic 
syndrome, through hormonal treatment, for a localised and stable prostate cancer that would 
not otherwise have required treatment. The urologists were initially reluctant to start hormo-
nal treatment because they were unconvinced that such a stable malignancy was associated 
with the membranous disease. After a discussion between the nephrologists and urologists, a 
trial of treatment was agreed upon, and subsequent complete remission of nephrotic syn-
drome was observed. It is, of course, possible that the membranous disease remitted sponta-
neously and the temporal association with hormonal treatment was coincidental. Male pa-
tients are at increased risk of deterioration in renal function [8]. He had heavy proteinuria for 
more than 6 months and patients with >8 g/day of proteinuria for more than 6–12 months 
have a 66% chance of developing renal insufficiency, which makes spontaneous remission in 
our case less likely [8]. There have been a number of case reports suggesting a possible asso-
ciation between membranous nephropathy and coeliac disease [9]. These reports all report 
the simultaneous onset of the two conditions. In our case, the coeliac disease was diagnosed 6 
years prior to the membranous nephropathy and remained stable on a gluten-free diet. As a 
result, we do not think that this association was relevant to our case. Androgen deprivation 
therapy has recently been reported in an Asian population with prostate cancer to decrease 
the risk of a number of autoimmune diseases but not primary membranous glomerulonephri-
tis [10]. There are no other reports of androgen deprivation therapy acting directly on mem-
branous nephropathy. 
In conclusion, this case highlights the importance of considering active treatment of low-
grade localised prostate cancer if an association with membranous disease is suspected and 
the importance of nephrologists acting as advocates for our patients with other clinical teams.  
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Fig. 1. Urine protein creatinine ratio and serum albumin levels over time before and after the introduction 
of bicalutamide therapy. 
 
